These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32113998)

  • 21. Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch.
    Ishikawa Y; Hosogane M; Okuyama R; Aoyama S; Onoyama I; Nakayama KI; Nakayama K
    Oncogene; 2013 Apr; 32(15):1921-32. PubMed ID: 22665065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FBXW7 in Cancer: What Has Been Unraveled Thus Far?
    Sailo BL; Banik K; Girisa S; Bordoloi D; Fan L; Halim CE; Wang H; Kumar AP; Zheng D; Mao X; Sethi G; Kunnumakkara AB
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30791487
    [No Abstract]   [Full Text] [Related]  

  • 23. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities.
    Davis RJ; Welcker M; Clurman BE
    Cancer Cell; 2014 Oct; 26(4):455-64. PubMed ID: 25314076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis.
    Onoyama I; Tsunematsu R; Matsumoto A; Kimura T; de Alborán IM; Nakayama K; Nakayama KI
    J Exp Med; 2007 Nov; 204(12):2875-88. PubMed ID: 17984302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7.
    Boretto M; Geurts MH; Gandhi S; Ma Z; Staliarova N; Celotti M; Lim S; He GW; Millen R; Driehuis E; Begthel H; Smabers L; Roodhart J; van Es J; Wu W; Clevers H
    Proc Natl Acad Sci U S A; 2024 Mar; 121(12):e2309902121. PubMed ID: 38483988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular insights and clinical implications for the tumor suppressor role of SCF
    Qi Y; Rezaeian AH; Wang J; Huang D; Chen H; Inuzuka H; Wei W
    Biochim Biophys Acta Rev Cancer; 2024 Jun; 1879(5):189140. PubMed ID: 38909632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant regulation of FBW7 in cancer.
    Wang L; Ye X; Liu Y; Wei W; Wang Z
    Oncotarget; 2014 Apr; 5(8):2000-15. PubMed ID: 24899581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis.
    Chong Z; Bao C; He J; Chen T; Zhong L; Li G; Li H; Fang L; Song Y; Fu G; Yang X; Lai L; Liu Y; Wang Q
    Cell Mol Immunol; 2018 Dec; 15(12):1057-1070. PubMed ID: 30275535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ubiquitin ligase FBXW7 targets the centriolar assembly protein HsSAS-6 for degradation and thereby regulates centriole duplication.
    Badarudeen B; Gupta R; Nair SV; Chandrasekharan A; Manna TK
    J Biol Chem; 2020 Apr; 295(14):4428-4437. PubMed ID: 32086376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The WD40 domain of FBXW7 is a poly(ADP-ribose)-binding domain that mediates the early DNA damage response.
    Zhang Q; Mady ASA; Ma Y; Ryan C; Lawrence TS; Nikolovska-Coleska Z; Sun Y; Morgan MA
    Nucleic Acids Res; 2019 May; 47(8):4039-4053. PubMed ID: 30722038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global and context-specific transcriptional consequences of oncogenic Fbw7 mutations.
    Thirimanne HN; Wu F; Janssens DH; Swanger J; Diab A; Feldman HM; Amezquita RA; Gottardo R; Paddison PJ; Henikoff S; Clurman BE
    Elife; 2022 Feb; 11():. PubMed ID: 35225231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients.
    Hagedorn M; Delugin M; Abraldes I; Allain N; Belaud-Rotureau MA; Turmo M; Prigent C; Loiseau H; Bikfalvi A; Javerzat S
    Cell Div; 2007 Feb; 2():9. PubMed ID: 17326833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fbxw7 haploinsufficiency loses its protection against DNA damage and accelerates MNU-induced gastric carcinogenesis.
    Jiang Y; Qi X; Liu X; Zhang J; Ji J; Zhu Z; Ren J; Yu Y
    Oncotarget; 2017 May; 8(20):33444-33456. PubMed ID: 28422719
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Tong J; Tan S; Nikolovska-Coleska Z; Yu J; Zou F; Zhang L
    Mol Cancer Ther; 2017 Sep; 16(9):1979-1988. PubMed ID: 28619760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.
    Cui D; Xiong X; Shu J; Dai X; Sun Y; Zhao Y
    Cell Rep; 2020 Jan; 30(2):497-509.e4. PubMed ID: 31940492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2.
    Nakajima T; Kitagawa K; Ohhata T; Sakai S; Uchida C; Shibata K; Minegishi N; Yumimoto K; Nakayama KI; Masumoto K; Katou F; Niida H; Kitagawa M
    J Biol Chem; 2015 Apr; 290(16):10368-81. PubMed ID: 25670854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The FBXW7 tumor suppressor inhibits breast cancer proliferation and promotes apoptosis by targeting MTDH for degradation.
    Chen X; Li XY; Long M; Wang X; Gao ZW; Cui Y; Ren J; Zhang Z; Liu C; Dong K; Zhang H
    Neoplasma; 2018; 65(2):201-209. PubMed ID: 29534580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent mutations in tumor suppressor
    Zhong Z; Virshup DM
    Sci Adv; 2024 Apr; 10(14):eadk1031. PubMed ID: 38569029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
    Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
    Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SCF
    O'Brien S; Kelso S; Steinhart Z; Orlicky S; Mis M; Kim Y; Lin S; Sicheri F; Angers S
    EMBO Rep; 2022 Dec; 23(12):e55044. PubMed ID: 36278408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.